Bristol Myers Squibb has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug Krazati, which targets what was once thought to be an elusive mutation in KRAS.
The drugmaker will pay $58 per share, according to a press release Sunday announcing the…
Click here to view original post
